Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
One objective of diabetes drugs is to assist the body in producing more insulin to better control blood glucose levels. The mean baseline blood insulin levels (expressed in µU/mL) were 11.2±4.1 ...
WASHINGTON — Eli Lilly's obesity ... rival Novo Nordisk's obesity drug Wegovy also gained Medicare coverage to reduce the risk of heart attacks and strokes. Lilly and Novo are testing ...
A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback